AstraZeneca announced a $300 million investment in a new facility in Rockville, Maryland, dedicated to discovering and developing cell therapies. This initiative will create more than 150 jobs in the United States and initially concentrate on manufacturing cell therapies for clinical trials, possibly expanding to support other disease areas in the future. This move is part of AstraZeneca’s ongoing commitment to cell therapy following its acquisition of Neogene Therapeutics and partnerships with other cell therapy developers. The company is also progressing with early-stage trials of several cell therapies targeting various types of cancer, including liver and prostate cancer.
To read more, click here.
[Source: Reuters, February 6th, 2024]